CancerDrs

Breast Cancer clinical trials in Missouri

39 actively recruiting breast cancer trials at 25 sites across Missouri.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Missouri:
  • Saint Francis Medical Center — Cape Girardeau, Missouri
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • MU Health - University Hospital/Ellis Fischel Cancer Center — Columbia, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • Parkland Health Center - Farmington — Farmington, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Missouri:
  • Mercy Oncology and Hematology - Clayton-Clarkson — Ballwin, Missouri
  • Central Care Cancer Center - Bolivar — Bolivar, Missouri
  • Cox Cancer Center Branson — Branson, Missouri
  • Mercy Cancer Center - Cape Girardeau — Cape Girardeau, Missouri
  • Saint Francis Medical Center — Cape Girardeau, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…

Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Missouri:
  • Research Site — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Missouri:
  • HCA Midwest Division — Kansas City, Missouri
  • Cancer Care Center of O'Fallon — O'Fallon, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Missouri:
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • University of Kansas Cancer Center - North — Kansas City, Missouri
  • University of Kansas Cancer Center - Lee's Summit — Lee's Summit, Missouri
  • Mercy Hospital Springfield — Springfield, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced…

Sponsor: AstraZeneca
NCT ID: NCT04862663
Sites in Missouri:
  • Research Site — Hannibal, Missouri
  • Research Site — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Missouri:
  • HCA Midwest Health — Kansas City, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…

Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Missouri:
  • Siteman Cancer Center - Washington University Medical Campus — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in Missouri:
  • Saint Luke's Cancer Institute — Kansas City, Missouri
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Missouri:
  • Saint Luke's Cancer Institute — Kansas City, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Missouri:
  • Clinical Trial Site — Kansas City, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

The Nanosomal Docetaxel Lipid Suspension (NDLS) consists of uniformly sized micro particles of docetaxel suspended in a lipid based formulation. The advantage of such a Lipid Based formulation of Docetaxel is an improvement of the safety p…

Sponsor: Jina Pharmaceuticals Inc.
NCT ID: NCT03671044
Sites in Missouri:
  • Cox Medical Center — Springfield, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Missouri:
  • Saint Francis Medical Center — Cape Girardeau, Missouri
  • Saint Luke's Hospital — Chesterfield, Missouri
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • Parkland Health Center - Farmington — Farmington, Missouri
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…

Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Missouri:
  • Saint Luke's Cancer Institute — Kansas City, Missouri
  • Washington University — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic…

Sponsor: Genentech, Inc.
NCT ID: NCT07100106
Sites in Missouri:
  • Washington University Siteman Cancer Center — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", whic…

Sponsor: Atossa Therapeutics, Inc.
NCT ID: NCT05607004
Sites in Missouri:
  • Washington University School of Medicine — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.

Sponsor: AstraZeneca
NCT ID: NCT06188520
Sites in Missouri:
  • Research Site — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

This study is a prospective evaluation of systemic, intravenous high-dose methotrexate (HD-MTX, 8 g/m2) in patients with triple negative, HER2-positive, and hormone refractory breast cancer with leptomeningeal metastasis (LMD) with or with…

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT02422641
Sites in Missouri:
  • Siteman Cancer Center- Washington University School of Medicine in St. Louis — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Multiple neoadjuvant endocrine trials demonstrate that women with good prognosis tumors can be identified. These trials have also demonstrated that there are not adverse effects on overall outcome if women are treated with neoadjuvant endo…

Sponsor: Washington University School of Medicine
NCT ID: NCT02476786
Sites in Missouri:
  • Washington University School of Medicine — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Missouri:
  • Saint Luke's Cancer Institute — Kansas City, Missouri
  • Washington University School of Medicine — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients w…

Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT05216432
Sites in Missouri:
  • Washington University School of Medicine St. Louis — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive …

Sponsor: Eli Lilly and Company
NCT ID: NCT07114601
Sites in Missouri:
  • Washington University — St Louis, Missouri
View on ClinicalTrials.gov →

Showing 25 of 39 trials with sites in Missouri. See all breast cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07